A practical reference on melanotan-2: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-05. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Cu2+ + 2 e− → Cu (cathode), E°cell = 0.34 V Copper sulfate is commonly included in teenage chemistry sets and undergraduate experiments. It is often used to grow crystals in schools and in Copper electroplating experiments despite its toxicity. Copper sulfate is often used to demonstrate an exothermic reaction, in which steel wool or magnesium ribbon is placed in an aqueous solution of CuSO4. It is used to demonstrate the principle of mineral hydration. The pentahydrate form, which is blue, is heated, turning the copper sulfate into the anhydrous form which is white, while the water that was present in the pentahydrate form evaporates. When water is then added to the anhydrous compound, it turns back into the pentahydrate form, regaining its blue color. Copper(II) sulfate pentahydrate can easily be produced by crystallization from solution as copper(II) sulfate, which is hygroscopic.
=== Vietnam war activism === During the 1960s, President Lyndon B. Johnson's policy of increasing America's involvement in the Vietnam War caused an anti-war movement that the Paulings joined with enthusiasm. Pauling denounced the war as unnecessary and unconstitutional. He made speeches, signed protest letters and communicated personally with the North Vietnamese leader, Ho Chi Minh, and gave the lengthy written response to President Johnson. His efforts were ignored by the American government.
== Philanthropy == The Dunkin' Joy in Childhood Foundation is an independent 501(c)3 charitable organization founded in 2006 to provide the simple joys of childhood to kids battling hunger or illness. The Foundation partners with food banks, children's hospitals, and nonprofit organizations to fund joyful environments and experiences for children across the country. Since its founding, the Foundation has granted more than $70 million to hundreds of national and local charities. Kari Bornhorst McHugh served as Executive Director from March 2017 to August 2021. In December 2018, McHugh launched the Dogs for Joy program, the first initiative of its scale to place full-time specially trained facility dogs in children's hospitals nationwide, backed by more than $2 million in initial grants. As part of the launch, McHugh brought in Cooper Dunkin', a Black Lab/Golden Retriever mix trained by Canine Assistants, who served as the Foundation's Chief Joy Officer and program ambassador, visiting children's hospitals across the country. In 2020, the Foundation launched Joyful Spaces, a program funding the creation and renovation of playgrounds, healing gardens, and play spaces at children's hospitals. Also during the COVID-19 pandemic, the Foundation introduced Hero Recharge, created in partnership with outdoor adventure nonprofit First Descents to support healthcare workers, which received an honorable mention in the Corporate Social Responsibility category of Fast Company's 2021 World Changing Ideas Awards.
Sources: en.wikipedia.org
Hormonal IUDs (referred to as intrauterine systems in the UK) work by releasing a small amount of levonorgestrel, a progestin. The progestin released by hormonal IUDs primarily acts locally within the uterus, resulting in much lower systemic progestin levels than other progestogen only contraceptives. Each type of hormonal IUD varies in size, amount of levonorgestrel released, and duration of effectiveness. The predominant mechanism of action of progestin in the uterus is thickening the cervical mucus to prevent sperm from reaching the fallopian tubes and ultimately the egg. Hormonal IUDs can also thin the endometrial (uterine) lining and potentially impair implantation, but this is not their usual function. Because they thin the endometrial lining, hormonal IUDs often reduce or entirely stop menstrual bleeding. As a result, they are often used to treat menorrhagia (heavy menses), once pathologic causes of menorrhagia (such as uterine polyps) have been ruled out.
The first large, diverse lineage of short-tailed avialans to evolve were the Enantiornithes, or "opposite birds", so named because the construction of their shoulder bones was in reverse to that of modern birds. Enantiornithes occupied a wide array of ecological niches, from sand-probing shorebirds and fish-eaters to tree-dwelling forms and seed-eaters. While they were the dominant group of avialans during the Cretaceous period, Enantiornithes became extinct along with many other dinosaur groups at the end of the Mesozoic era. Many species of the second major avialan lineage to diversify, the Euornithes (meaning "true birds", because they include the ancestors of modern birds), were semi-aquatic and specialised in eating fish and other small aquatic organisms. Unlike the Enantiornithes, which dominated land-based and arboreal habitats, most early euornithians lacked perching adaptations and likely included shorebird-like species, waders, and swimming and diving species. The latter included the superficially gull-like Ichthyornis and the Hesperornithiformes, which became so well adapted to hunting fish in marine environments that they lost the ability to fly and became primarily aquatic. The early euornithians also saw the development of many traits associated with modern birds, like strongly keeled breastbones, toothless, beaked portions of their jaws (though most non-avian euornithians retained teeth in other parts of the jaws).
=== CSIR India === In 2009, Ayyadurai was hired by India's Council of Scientific and Industrial Research (CSIR), India's largest science agency, by its director general, Samir K. Brahmachari. CSIR was mandated to create a new company, CSIR Tech, that would establish businesses using the research conducted by the country's many publicly owned laboratories. Ayyadurai reported that he had spent months trying to create a business plan for CSIR Tech, but received no response from Brahmachari. Ayyadurai then distributed a draft plan, which was not authorized by CSIR, to the agency's scientists that requested feedback and criticized management. His job offer was subsequently withdrawn five months after the position was offered. Brahmachari said that "the offer was withdrawn as [Ayyadurai] did not accept the terms and conditions and demanded unreasonable compensation." In its report, The New York Times said that "going public with such accusations is highly unusual. Mr. Ayyadurai circulated his paper not just to the agency's scientists but to journalists, and wrote about his situation to Prime Minister Manmohan Singh." In that letter, Ayyadurai said his report was intended to explore institutional barriers to CSIR's entrepreneurial mandate. He said that CSIR scientists reported that "they work in a medieval, feudal environment" that required a "major overhaul". The letter was co-authored by a colleague, Deepak Sardana.
Sources: en.wikipedia.org
In terms of the effects of progestogens on sex drive, one study assessed the use of dydrogesterone to improve sexual desire in transgender women and found no benefit. Another study likewise found that oral progesterone did not improve sexual function in cisgender women. Progestogens can have adverse effects. Oral progesterone has inhibitory neurosteroid effects and can produce side effects such as sedation, mood changes, and alcohol-like effects. Many progestins have off-target activity, such as androgenic, antiandrogenic, glucocorticoid, and antimineralocorticoid activity, and these activities likewise can contribute unwanted side effects. Furthermore, the addition of a progestin to estrogen therapy has been found to increase the risk of blood clots, cardiovascular disease (e.g., coronary heart disease and stroke), and breast cancer compared to estrogen therapy alone in postmenopausal women. Although it is unknown if these health risks of progestins occur in transgender women similarly, it cannot be ruled out that they do. High-dose progestins increase the risk of benign brain tumors including prolactinomas and meningiomas as well. Because of their potential detrimental effects and lack of supported benefits, some researchers have argued that, aside from the purpose of testosterone suppression, progestogens should not generally be used or advocated in transgender women or should only be used for a limited duration (e.g., 2–3 years).
On 16 November, Olivey decided that holding the point any longer was pointless and ordered his men to split up, escape by any means possible and re-assemble in Cairo. Over half of the unit reached Egypt.
== Mechanism of toxicity == Once azinphos-methyl is absorbed it can cause neurotoxic effects, like other organophosphate insecticides. At high concentrations AzM itself can be toxic because it can function as an acetylcholinesterase (AChE) inhibitor. But its toxicity is mainly due to the bioactivation by a cytochrome P450 (CYP450)-mediated desulfuration to its phosphate triester or oxon(gutoxon) (see figure 2). Gutoxon can react with a serine hydroxyl group at the active site of the AChE. The active site is then blocked and AChE is inactivated. Under normal circumstances acetylcholinesterase rapidly and efficiently degrades the neurotransmitter acetylcholine (ACh) and thereby terminates the biological activity of acetylcholine. Inhibition of AChE results in an immediate accumulation of free unbound ACh at the ending of all cholinergic nerves, which leads to overstimulation of the nervous system.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.